medigraphic.com

2006, Number 4

<< Back Next >>

Vet Mex 2006; 37 (4)

Production of vaccines and other biological compounds in transgenic plants

Loza-Rubio E, Gómez-Lim MA

Language: English/Spanish
References: 88
Page: 441-445
PDF size: 294.97 Kb.


ABSTRACT

Even though plants have been utilized by man for medicinal purposes for thousands of years, it is only recently that by using genetic engineering they have been employed as “biofactories” or “biorreactors” to produce compounds of pharmaceutical interests. Considering the increased demand for these type of products all over the world, this technology is being increasingly employed. Nowadays, the high cost of many pharmaceutical compounds limits their distribution and applicability; however, by using transgenic plants, the cost can be considerably reduced, the product easy to store, production can be scaled up or down, and products will be safer than those produced in other systems.


REFERENCES

  1. Babiuk LA, Babiuk SL, Loehr BI, van Drunnen S, van den Hurk L. Nucleic acid vaccines: research tool or commercial reality. Vaccine 2000;76:1-23.

  2. Daniell, H, Streatfi eld SJ, Wycoff K. Medical molecu-lar farming: production of antibodies, biopharmaceu-ticals and edible vaccines in plants. Trends Plant Sci 2001;6:219-226.

  3. Binnie C, Cossar JD, Stewart DIH. Heterologous bio-pharmaceutical protein expression in Streptomyces. Trends Biotechnol 1997;15:315-320.

  4. Birch RG. Plant transformation: Problems and strate-gies for practical application. Ann Rev Plant Physiol Plant Mol Biol 1997;48:297-326.

  5. Koprowski H, Yusibov V. The green revolution:plants as heterologous expression vectors. Vaccine;2001:2735-2741.

  6. Kaufman PB, Wu W. Gene transfer and expression in plants. In: Kaufman PB, Wu W, editors. Molecular and cellular methods in biology and medicine. Florida, USA:CRC Press, 1995:367-393.

  7. Breitler JC, Labeyrie A, Meynard D, Legavre T, Guider-doni E. Effi cient microprojectile bombardment-medi-ated transformation of rice using gene cassettes. Theor Appl Genet 2002;104:709-719.

  8. Kohli A, Twyman RM, Abranches R, Wegel E, Stoger E, Christou P. Transgenic integration, organization and interaction in plants. Plant Mol Biol 2003;52:247-258.

  9. Potenza C, Aleman L, Sengupta-Copalan C. Target-ing transgene expresion in research, agricultural, and environmental applications: promoters used in plant transformation. In vitro Cell Dev Biol 2004;40:1-22.

  10. Wigdorovitz A, Perez-Filgueira DM, Robertson N, Car-rillo C, Sadir AM, Morris TJ et al. Induction of a pro-tective antibody response to foot and mouth disease in mice following oral or parenteral immunization with alfalfa transgenic plants expressing the viral structural protein VP1. Virology 1999;255, 347–353.

  11. Sala F, Rigano MM, Barbante A, Basso B, Walmsley AM, Castiglione S. Vaccine antigen production in transgenic plants: strategies, gene constructs and per-spectives. Vaccine 2003;21:803-806.

  12. Voinnet O, Rivas S, Mestre P, Baulcombe D. An enhanced transient expression system in plants based on suppression of gene silencing by the p 19 protein of tomato bushy stunt virus. Plant J 2003;33:949-956.

  13. Khoudi H, Laberge S, Ferullo JM, Bazin R, Darveau A, Castonguay Y et al Production of a diagnostic mono-clonal antibody in perennial alfalfa plants. Biotechnol Bioeng 1999; 64, 135–143.

  14. Kusnadi A, Nikolov R, Zivko L, Howard JA. Production and purifi cation of recombinant proteins in transgenic plants: practical considerations. Biotechnol Bioeng 1998;56,473–484.

  15. Hood EE, Kusnadi A, Nikolov Z, Howard JA. Molecular farming of industrial proteins from transgenic maize. Adv Exp Med Biol 1999;464:127-147.

  16. Larrick JW, Ju L, Chen J, Jaiswal S, Wycoff K. Produc-tion of antibodies in transgenic plants. Ress Immunol 1998;149:603-608.

  17. Larrick JW, Thomas DW. Producing proteins in transgenic plants and animals. Curr Op Biotechnol 2001;12:411-418.

  18. Lamphear BJ, Streatfi eld SJ, Jilka JM, Brooks CA, Barker DK, Turner DD et al. Delivery of subunit vac-cines in maize seed. J Control Rel 2002;85:169-180.

  19. Staub JM, Garcia B, Graves J, Hajdukiewicz PT, Hunter P, Nehra N et al. High-yield production of a human therapeutic protein in tobacco chloroplasts. Nat Bio-technol 2000;18, 333–338.

  20. De Cosa B, Moar W, Lee SB, Miller M, Daniell H. Over-expression of the Bt cry2Aa2 operon in chloroplasts leads to formation of insecticidal crystals. Nat Biotech-nol 2001;19:71-74.

  21. Kang TJ., Loc NH, Jang MO, Jang YS, Kim YS, Seo JE et al. Expression of the B subunit of E. coli heat-labile enterotoxin in tobacco chloroplasts of plants and its characterization. Transgenic Res 2003;12:683-691.

  22. Zhong GY, Peterson D, Delaney DE, Bailey M, Wichter DR, Register JC et al. Commercial production of apro-tinin in transgenic seeds. Mol Breed 1999;5:345-356.

  23. Valdes R, Gomez L, Padilla S, Brito J, Reyes B, Alva-rez T et al. Large purifi cation of an antibody directed against hepatitis B surface antigen from transgenic tobacco plants. Biochem Biophys Res Commun 2003; 308:94-100.

  24. Fischer R, Twyman RM, Schillberg S. Production of antibodies in plants and their use for global health. Vaccine 2003;21:820-825.

  25. Stöger E, Vaquero C, Torres E, Sack M, Nicholson L, Drossard J et al. Cereal crops as viable production and storage systems for pharmaceutical scFv antibodies. Plant Mol Biol 2000;42: 583–590.

  26. Ma J, Hiatt A, Hein M, Vine ND, Wang F, Stabila P. Generation and assembly of secretory antibodies in plants. Science 1995;268:716–719.

  27. Artsaenko O, Kettig B, Fiedler U, Conrad U, Düring K. Potato tubers as a biofactory for recombinant antibod-ies. Mol Breed 1998;4:313–319.

  28. Ma J, Hikmat B, Wycoff K, Vine N, Chargelegue D, Yu L et al. Characterization of a recombinant plant mono-clonal secretory antibody and preventive immunother-apy in humans. Nat Med 1998;4:601–606.

  29. Zeitlin L, Olmsted SS, Moench TR, Co MS, Marti-nell BJ, Paradkar VM et al. A humanized monoclonal antibody produced in transgenic plants for immuno-protection of the vagina against genital herpes. Nat Biotechnol 1998;16: 1361–1364.

  30. De Wilde C, Van Houdt H, de Buck S, Angenon G, de Jaeger G, Depicker A. Plants as bioreactors for protein production: avoiding the problem of transgene silenc-ing. Plant Biol Mol 2000;43:361-376.

  31. Cabanes-Macheteau M, Fitchette-Laine AC, Loutelier-Bourchis C, Lange C, Vine ND, Ma JK et al. N-glycosyl-ation of a mouse IgG expressed in transgenic tobacco plants. Glycobiology 1999;9:365–372.

  32. Vaquero C, Sack M, Chandler J, Drossard J, Schuster F, Monecke M et al. Transient expression of a tumor-specifi c single-chain fragment and a chimeric anti-body in tobacco leaves. Proc Natl Acad Sci USA 1999; 96:11128–11133.

  33. Thomas JA. Safety of foods derived from genetically modifi ed plants. Tex Med 2003;99:66-69.

  34. Mor TS, Sternfeld M, Arntzen CJ, Mason HS. Expres-sion of recombinant human acetylcholinesterase in transgenic tomato plants. Biotechnol Bioeng 2001;75:259-266.

  35. Mason HS, Warzecha H, Mor T, Arntzen CJ. Edible plant vaccines: applications for prophylactic and therapeutic molecular medicine. Trends Mol Med 2002:8:324-329.

  36. Haq TA, Mason HS, Clements JD, Arntzen CJ. Oral immunization with a recombinant bacterial antigen produced in transgenic plants. Science 1995;268:714–716.

  37. Mason, HS Arntzen C. Expression of hepatitis B sur-face antigen in transgenic plants. Proc Natl Acad Sci USA 1992;89:11745–11749.

  38. Mason, HS, Ball JM, Shi JJ, Jiang X, Estes MK, Arntzen CJ. Expression of Norwalk virus capsid protein in trans-genic tobacco and potato and its oral immunogenicity in mice. Proc Natl Acad Sci USA 1996;93:5335–5340.

  39. Mc Garvey PB, Hammond J, Dienelt MM, Hooper DC, Fu ZF, Dietzschold B et al. Expression of the rabies virus glycoprotein in transgenic tomatoes. Biotechnol-ogy 1995;13:1484–1488.

  40. Arakawa T, Chong DKX, Langridge WHR. Effi cacy of a food plant-based oral cholera toxin B subunit vac-cine. Nat Biotechnol 1998;16:292–297.

  41. Carrillo C, Wigdorovitz A, Oliveros JC, Zamorano PI, Sadir AM, Gomez N et al. Protective immune response to foot-and-mouth disease virus with VP1 expressed in transgenic plants. J. Virol. 1998;72:1688–1690.

  42. Gomez N, Carrillo C, Parra F, Salinas J, Borca MV, Escribano JM. Expression of immunogenic glyco-protein S polypeptides from transmissible gastro-enteritis coronavirus in transgenic plants. Virology 1998;249:352–358.

  43. Mason, H.S, Haq TA, Clements JD, Arntzen CJ. Edible vaccine protects mice against Escherichia coli heat-labile enterotoxin (LT): potatoes expressing a synthetic LT-B gene. Vaccine 1998;16:1336–1343.

  44. Thanavala Y, Wang YF, Lyons P, Mason HS, Arntzen CJ. Immunogenicity of transgenic plant-derived hepatitis B surface antigen. Proc Natl Acad Sci USA 1995; 92: 3358–3361.

  45. Tacket CO, Mason HS, Losonky G, Clements JD, Levine MM, Arntzen CJ. Immunogenicity in humans of a recombinant bacterial antigen delivered in a trans-genic potato. Nat Med 1998;4:607–609.

  46. Kapusta J, Modelska A, Figlerowicz M, Pniewski T, Letellier M, Lisowa O et al. A plant-derived edible vac-cine against hepatitis B virus. FASEB J. 1999;13:1796–1799.

  47. Castanon S, Marin MS, Martin-Alonso JM, Boga JA, Casals R, Humara JM, et al. Immunization with potato plants expressing VP60 protein protects against rabbit hemorrhagic disease virus. J. Virol 1999; 73: 4452–4455.

  48. Tuboly T, Yu W, Bailey A, Degrandis S, Du S, Erickson L, et al. Immunogenicity of porcine transmissible gas-troenteritis virus spike protein expressed in plants. Vaccine 2000;18: 2023–2028.

  49. Streatfi eld SJ, Jilka JM, Hood EE, Turner DD, Bailey ME, Mayor JM et al. Plant-based vaccines: unique advantages. Vaccine 2001;19:2742–2748.

  50. Yusibov V, Hooper DC, Spitsin SV, Fleysh N, Kean RB, Mikheeva T et al. Expression in plants and immunogenicity of plant virus-based experimental rabies vac-cine. Vaccine 2002;20:3155-3164.

  51. Bonetta L. Edible vaccines:not quite ready for prime time. Nat Med 2002;8:94.

  52. Plana-Duran J, Bastons M, Rodríguez MJ, Climent I, Cortes E, Vela C et al. Oral immunization of rabbits with VP60 particles confers protection against rabbit hemorrhagic disease. Arch Virol 1996;141:1423-1436.

  53. Khandelwal A, Sita SG, Shaila MS. Expression of hem-agglutinin protein of rinderpest virus in transgenic tobacco and immunogenicity of plant-derived protein in a mouse model. Virology 2003;308:207-215.

  54. Dos Santos MJ, Wigdorovitz A, Trono K, Rios RD, Fran-zone PM, Gil F et al. A novel methodology to develop a foot and mouth disease virus (FMDV) peptide-based vaccine in transgenic plants. Vaccine 2002;20:1141-1147.

  55. Rossi L, Baldi A, Dell’Orto V, Fogher C. Antigenic recombinant proteins expressed in tobacco seeds as a model for edible vaccines against swine oedema. Vet Res Comm 2003; S27:659-661.

  56. Dalsgaard K, Uttenthal A, Jones TD, Xu F, Merry-weather A, Hamilton WDC et al. Plant-derived vaccine protects target animals against a viral disease. Nat Bio-technol 1997;15:248-252.

  57. Nicholas BL, Brennan FR, Martinez-Torrescuadra JL, Casal JI, Hamilton WD, Wakelin D. Characterization of the immune response to canine parvovirus induced by vaccination with chimaeric plant viruses. Vaccine 2002;20:2727-2734.

  58. Modelska A, Dietzschold B, Fleysh N, Fu ZF, Steplewski K, Hooper C et al. Immunization against rabies with plant-derived antigen. Proc Natl Acad Sci USA 1998;95:2481-2485.

  59. Loza-Rubio E, Saucedo LJ, Aguirre O, Olivera FMT, Gomez-Lim MA. Rabies vaccine expressed in trans-genic maize plants: Construction of vectors. 12th Annual Rabies in the Americas Conference; 2001 November 12-16; Peterborough (ON), Canada, Ontario): WHO,CDC,SSA, 2001:64.

  60. Alonso LCC, Scharton TM, Viera LZ, Wysocka M, Trinchieri G, Scott P. The adjuvant effect of interleu-kin-12 in a vaccine against Leishmania major. Science 1994;263: 235-237.

  61. Noguchi Y, Richards, EC Chen, YT Old LJ. Infl uence of interleukin-12 on p53 peptide vaccination against established Meth A sarcoma. Proc. Natl. Acad. Sci. USA 1995;92: 2219-2223.

  62. Bokaya PN, Marinaro MR, Jackson RJ, Menon S, Kiyono Jirillo, E. et al. II-12 is an effective adjuvant for induc-tion of mucosal immunity. J Immunol 1999;162:122-128.

  63. Wang Y, Wang W, Li N, Yu Y, Cao X. Activation of antigen-presenting cells by immunostimulatory plant DNA: a natural resource for potencial adjuvant. Vac-cine 2002;20:2764-2771.

  64. Arakawa T, Chong DKX, Merrit JL, Langridge WHR.Expression of cholera toxin B subunit oligomers in transgenic potato plants. Transgenic Res 1997;6:403–413.

  65. Richter LJ, Thanavala Y, Arntzen CJ, Mason HS. Produc-tion of hepatitis B surface antigen in transgenic plants for oral immunization. Nat Biotechnol 2000;18:1167–1171.

  66. Tackaberry ES, Dudani AK, Prior F, Tocchi M, Sardana R, Altosaar I et al. Development of biopharmaceuticals in plant expression systems: cloning, expression and immunological reactivity of human cytomegalovirus glycoprotein B (UL55) in seeds of transgenic tobacco. Vaccine 1999;17:3020–3029.

  67. Tacket CO, Mason HS, Losonsky G, Estes MK, Levine MM, Arntzen CJ. Human immune responses to a novel Norwalk virus vaccine delivered in transgenic potatoes. J Infect Dis 2000;182:302–305.

  68. Daniell H. GM crops: public perception and scientifi c solutions. Trends Plant Sci 1999;4: 467–469.

  69. Puchta, H. Removing selectable marker genes: taking the shortcut. Trends Plant Sci. 2000;5:273–274.

  70. Ma J, Hiatt A, Hein M, Vine ND, Wang F, Stabila P. Gen-eration and assembly of secretory antibodies in plants. Science 1995; 268: 716–719.

  71. Ma J, Hikmat B, Wycoff K, Vine N, Chargelegue D, Yu L, et al. Characterization of a recombinant plant mono-clonal secretory antibody and preventive immunother-apy in humans. Nat. Med 1998;4:601–606.

  72. Mc Cormick AA, Kumagai MH, Hanley K, Turpen TH, Hakim I, Grill LK et al. Rapid production of specifi c vac-cines for lymphoma by expression of the tumor-derived single-chain Fv epitopes in tobacco plants. PNAS USA 1999;96:703-708.

  73. Bouquin T, Thomsen M, Green TH, Mundy J, Hanefeld Dziegiel M. Human anti-rhesus D IgG1 antibody pro-duced in transgenic plants. Transgenic Res 2002;11:115-122.

  74. Ko O, Tekoah Y, Rudd PM, Harvey DJ, Dwek RA, Spitsin S et al. Function and glycosilation of plant-derived anti-viral monoclonal antibody. PNAS USA 2003;100:8013-8018.

  75. Bouche FB, Marquet-Blouin E, Yanagi Y, Steinmetz A, Muller CP. Neutralising immunogenicity of a poly-epitope antigen expressed in a transgenic food plant: a novel antigen to protect against measles. Vaccine 2003;21:2065-2072.

  76. Azhar AM, Singh S, Kumar PA, Bhatnagar R. Expres-sion of protective antigen in transgenic plants: a step towards edible vaccine against anthrax. Biochem Bio-phys Res Commun 2002;299:345-351.

  77. Giddings G, Allison G, Brooks D, Carter A. Transgenic plants as factories for biopharmaceuticals. Nat Biotech-nol 2000;18:1151–1155.

  78. Sandhu JS, Krasnyanski SF, Domier LL, Korban SS, Osadjan MD, Buetow DE. Oral immunization of mice with transgenic tomato fruit expressing respiratory sincytial virus-F protein induces a systemic immune response. Transgenic Res 2000;9:127-135.

  79. Warzecha H, Mason HS, Lane C, Tryggvesson A, Rybicki E, Williamson AL et al. Oral immunogenicity of human papillomavirus-like particles expressed in potato. J Virol;2003:8702-8711.

  80. Biemelt S, Sonnewald U, Galmbacher P, Willmitzer L, Muller M. Production of human papillomavirus type 16 virus-like particles in transgenic plants. J Virol 2003;77:9211-9220.

  81. Varsani A, Williamson AL, Rose RC, Jaffer M, Rybicki EP. Expression of human papillomavirus type 16 major capsid protein in transgenic Nicotiana tabacum cv. Xanthi. Arch Virol 2003;148:1771-1786.

  82. Wu L, Li JT, Mou ZR, Fei L, Ni B, Geng M et al. Oral immunization with rotavirus VP7 expressed in trans-genic potatoes induced high titers of mucosal neutral-izing IgA. Virology 2003;313:337-342.

  83. Martin-Alonso JM, Castanon S, Alonso P, Parra F, Ordas R. Oral immunization using tuber extracts from transgenic potato plants expressing rabbit hem-orrhagic disease virus capsid protein. Transgenic Res 2003;12:127-130.

  84. Wu L, Jiang L, Zhou Z, Fan J, Zhang Q, Zhu Q et al. Expression of foot and mouth disease virus epit-.opes in tobacco mosaic virus-based vector. Vaccine 2003;21:4390-4398.

  85. Giddings G, Allison G, Brooks D, Carter A. Transgenic plants as factories for biopharmaceuticals. Nat Biotech-nol 2000;18:1151–1155.

  86. Ruggiero F, Exposito JY, Bournat P, Gruber V, Perret S, Comte J et al. Triple helix assembly and processing of human collagen produced in transgenic tobacco plants. FEBS Lett 2000;469:132–136.

  87. Chong DK, Langridge WH. Expression of full length bioactive antimicrobial human lactoferrin in potato plants. Transgenic Res 2000; 9: 71–78.

  88. Gutierrez OA, Avila MF, Saucedo ALJ, Sanchez TC, Gomez-Lim MA. Expression of a single-chain human interleukin-12 gene in transgenic tobacco plants and functional studies. Biotechnol Bioeng 2004;85:734-740.




2020     |     www.medigraphic.com